XENETIC BIOSCIENCES INC (XBIO) Stock News

USA - Nasdaq - NASDAQ:XBIO - US9840156023 - Common Stock

2.52 USD

+0.07 (+2.86%)

Last: 12/2/2025, 9:46:33 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

XBIO Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Benzinga - Mentions: BLRX BRTX IBO VNRX ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

13 days ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform

19 days ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

2 months ago - By: Benzinga - Mentions: MU GLTO

Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges

4 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

7 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

9 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

2 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

4 months ago - By: Zacks Investment Research - Mentions: CASI

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

4 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

5 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic

8 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

8 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

9 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

9 months ago - By: ACCESS Newswire

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting